The new analysis, published in BMC Pediatrics by Yılmaz Seçilmiş, Gülşah Kartal and Muhammet Sami Kayan of Erciyes University in Kayseri, Türkiye, takes the form of a scoping review. Following the Joanna Briggs Institute methodology and reporting to the PRISMA-ScR standard, the team searched PubMed, Scopus and Web of Science on 14 March 2026 without date or language restrictions, supplementing the search with hand-searching that included regional Turkish journals. Their PROSPERO-registered protocol (CRD420261340727) focused on a very specific triad: individual cases of methemoglobinemia following prilocaine administered for circumcision in infants aged zero to twelve months. Two reviewers screened studies independently, achieving an inter-rater agreement of kappa equal to 0.849, a level conventionally regarded as very strong.

The search identified twenty-four studies published between 1989 and 2026 that together documented thirty-eight cases. Strikingly, thirty-three of those cases—86.8 percent—came from Türkiye, a concentration the authors caution reflects the geography of the published literature rather than any measured difference in incidence. No reliable incidence rate can be extracted from case reports, which are subject to publication bias: dramatic recoveries get written up, routine events do not. Still, the consistency of the clinical picture across reports is what makes the review valuable. In every single case that reported presentation details, the defining feature was the same: cyanosis that did not respond to oxygen therapy, the classic fingerprint of methemoglobinemia.

The biochemistry explains why oxygen fails. Under normal conditions, hemoglobin carries iron in its ferrous (Fe2+) state, binding oxygen in the lungs and releasing it in tissues. Oxidizing agents can convert some of that iron to the ferric (Fe3+) state, producing methemoglobin, which binds oxygen tightly but cannot unload it. Worse, methemoglobin shifts the oxygen-dissociation curve of the remaining normal hemoglobin to the left, compounding the tissue hypoxia. Infants are especially vulnerable because their red cells contain fetal hemoglobin, which oxidizes more readily, and because the NADH-dependent reductase pathway that normally reduces methemoglobin back to hemoglobin is not fully mature in the first months of life. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is more common in some populations, adds a further layer of susceptibility.

Prilocaine enters this picture because it is an amide local anesthetic whose metabolites, notably o-toluidine, are known oxidizing agents capable of overwhelming red-cell defenses. In the reviewed cases, prilocaine was given by injection—typically as a dorsal penile nerve block or subcutaneously—in 89.5 percent of reports, while 10.5 percent involved topical application of EMLA, the eutectic mixture of lidocaine and prilocaine that is widely marketed for procedural pain relief in infants. Both routes have been implicated, though dosing detail was surprisingly scarce: the prilocaine dose was reported in only 44.7 percent of cases, a gap the authors highlight as a failure of case-report completeness with direct consequences for understanding dose-response relationships.

The severity of the episodes was considerable. Among thirty-seven cases with laboratory data, the mean methemoglobin fraction was 33.6 percent, with individual values ranging from 11.9 to 62.0 percent. Normal levels sit below about one to two percent, and clinical signs such as cyanosis generally appear above ten to fifteen percent, with levels above roughly thirty percent considered clinically significant and above fifty percent potentially life-threatening. That the reported episodes reached such heights underscores how quickly a routine analgesic injection in a healthy infant can escalate into a pediatric emergency requiring immediate recognition and intervention.

Treatment in the published cases followed two main paths. Methylene blue, the established first-line antidote for clinically significant acquired methemoglobinemia, was administered in twenty cases. The drug works as an exogenous electron carrier, accepting electrons from NADPH via the hexose monophosphate shunt and reducing methemoglobin back to functional hemoglobin—essentially providing the infant red cell with an enzymatic shortcut it cannot yet perform efficiently on its own. Ascorbic acid, a slower-acting reducing agent described mainly in isolated reports and sometimes used as adjunctive therapy, was given in twenty-one cases, either alone or in combination with methylene blue. Every published case ended in full recovery, but the authors are careful to note that uncontrolled case reports cannot disentangle the effects of treatment from spontaneous recovery, supportive care, or the natural course of the condition, and no claim of comparative efficacy between antidotes can be made from such data.

To widen the lens beyond the formal case literature, the team also queried three major pharmacovigilance databases: the World Health Organization’s VigiBase, the US Food and Drug Administration’s FAERS, and the European EudraVigilance system. These spontaneous-report databases contained reports extending beyond the circumcision-specific literature, including some with fatal outcomes. The authors treat these as contextual reference only, stressing that spontaneous reports cannot confirm causality, cannot verify the procedural context, and must not be used as a quantitative comparator. The distinction matters: pharmacovigilance signals can justify scrutiny, but they are not evidence of risk magnitude, and conflating them with verified clinical case series distorts the risk picture for both clinicians and parents.

The completeness assessment is one of the review’s most practically useful contributions. Methemoglobin level and treatment were each documented in 97.4 percent of cases, reflecting awareness that both are central to the diagnosis and management narrative. But the prilocaine dose was reported in fewer than half the cases, and other details—timing of onset, use of screening for G6PD deficiency, cumulative exposure, and follow-up—varied widely. The authors argue that better-structured case reporting would allow future syntheses to move beyond description toward genuine risk characterization. Their quality appraisal used the Murad et al. tool for case reports, and the full charted dataset, search strategy and PRISMA-ScR checklist are available as supplementary files with the open-access article.

For clinical practice, the authors’ conclusions are measured rather than alarmist. The published reports describe a recurring, recognizable presentation—cyanosis poorly responsive to oxygen in a recently anesthetized infant—but cannot establish how often it occurs or which treatment is superior. Methylene blue remains the established first-line antidote for clinically significant acquired methemoglobinemia. Depending on the clinical context, indication and dose, minimizing prilocaine exposure and observing infants for post-procedure cyanosis may be considered, with clinical decisions individualized. The uniformly positive outcomes recorded in the literature, the team warns, may well reflect publication and survivorship bias rather than an inherently benign course. In other words, the absence of documented deaths in the case series should not be read as reassurance; it may simply mean that the worst outcomes go unreported. The review received no specific funding, and the authors declare no competing interests. Its message for clinicians is simple and urgent: when a circumcised infant turns blue and oxygen does not help, think methemoglobinemia, check a methemoglobin level, and act fast.

Subject of Research: Prilocaine-associated methemoglobinemia in neonates and infants undergoing circumcision

Article Title: Prilocaine-associated methemoglobinemia after neonatal and infant circumcision: a scoping review of published cases with pharmacovigilance context

Article References: Seçilmiş, Y., Kartal, G., & Kayan, M. S. (2026). Prilocaine-associated methemoglobinemia after neonatal and infant circumcision: a scoping review of published cases with pharmacovigilance context. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07741-2

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07741-2

Keywords: prilocaine, methemoglobinemia, circumcision, neonates, infants, methylene blue, ascorbic acid, EMLA cream, pharmacovigilance, scoping review, cyanosis, pediatric emergency

General anesthesia in children is fraught with unique challenges. Unlike adults, the pediatric patient population often displays different physiological responses to anesthetic agents, necessitating meticulously tailored approaches to ensure safety and effectiveness. The introduction of HR020602 marks an important milestone in this field, as researchers aim to address both efficacy and safety concerns associated with anesthesia in young patients. The primary objective of this study is to establish a new standard by assessing how HR020602, when used alongside propofol, influences outcomes in pediatric patients subjected to anesthesia.

In this phase 2 study published in BMC Pediatrics, the researchers meticulously evaluated outcomes from multiple institutions, bringing together a wealth of data to support their hypotheses. The study aimed not only to quantify the efficacy of HR020602 but also to evaluate its safety profile through rigorous monitoring of adverse events and recovery parameters in a real-world clinical setting. This approach allows for a comprehensive understanding of how the combination of these agents impacts both the short-term and long-term well-being of children facing surgical procedures.

The methodology utilized in the study was robust. Participants were carefully selected, with strict inclusion and exclusion criteria to ensure that the results would be as reliable as possible. An array of clinical sites contributed data, which facilitates a wide applicability of the findings owing to the diversity in institutional practices and patient demographics. The researchers employed various assessment tools to evaluate anesthesia depth, recovery times, and incidence of postoperative complications, making this study one of the most thorough to date in the realm of pediatric anesthesia.

As the study progressed, accumulating evidence began to point toward a promising narrative. Initial findings suggested that the combination of HR020602 with standard propofol anesthesia resulted in favorable outcomes that were statistically significant when compared to the control groups. Notably, metrics such as time to emergence and postoperative nausea and vomiting were diligently documented, offering insights into the operational efficacy of HR020602. The implications of these findings are profound, not just for managing anesthetic strategies, but also for enhancing the overall surgical experience for children and their families.

The safety considerations surrounding anesthetic practices in children cannot be understated. Tender age, physiological development, and the psychological impact of surgery necessitate an anesthetic care model that prioritizes safety above all. Through acute surveillance for any adverse reactions associated with HR020602, the study strives to dispel any anxieties regarding new drug use in pediatric settings. Early results indicated a favorable safety profile, laying the groundwork for further exploration and potential integration into pediatric anesthesia protocols.

The findings of this study reverberate beyond immediate clinical implications. They tap into a larger dialogue concerning the ongoing evolution of anesthetic practices, emphasizing the need for continual innovation as advancements in medicine propel us towards safer and more efficient treatments. Pediatric anesthetists have long awaited breakthroughs that can help bridge the gap between pediatric and adult anesthetic practices while addressing the unique challenges inherent to treating younger patients. HR020602, as suggested by preliminary results, holds the potential to be a game-changer in this field.

As researchers continue to dissect the data, the overarching theme remains centered on improving outcomes for children during surgery, a critical aspect not only in medicine but in the wellbeing of families as well. Effective communication of study findings to both the medical community and the public can facilitate an informed approach toward the implementation of new anesthetic protocols. Educating families about the safety measures and advancements such as HR020602 is equally essential in nurturing trust and understanding within the pediatric surgical context.

Looking ahead, the journey of HR020602 through clinical practice is at a nascent stage. Subsequent studies and real-world applications will be imperative for validating the current findings and translating them into routine clinical use. Continuous assessment and reporting will provide vital information, allowing caregivers to weigh the benefits against risks in a dynamic and evolving healthcare landscape where safety remains paramount.

In summary, this groundbreaking study is not merely an exploration of a new drug but a critical examination of how far pediatric anesthesia has come and where it is heading. Utilizing innovative agents like HR020602 alongside established standards such as propofol is a strategic move towards enhancing the overall quality of healthcare delivered to young patients. As more data becomes available, the potential ramifications of such studies will catalyze new conversations surrounding anesthesia practices, underscoring the importance of collaborative research efforts in understanding and implementing the optimal care paradigms for children.

As we await the broader implications of this research, one thing remains evident: the commitment to safety and efficacy in pediatric anesthesia will remain at the forefront of medical advancements, ensuring that the next generation receives the best possible care.

Subject of Research: Pediatric Anesthesia

Article Title: Efficacy and safety of HR020602 in combination with propofol in children receiving general anesthesia: a multicenter, phase 2 study.

Article References:

Zou, N., Wang, X., Wang, F. et al. Efficacy and safety of HR020602 in combination with propofol in children receiving general anesthesia: a multicenter, phase 2 study.
BMC Pediatr (2026). https://doi.org/10.1186/s12887-025-06495-7

Image Credits: AI Generated

DOI: 10.1186/s12887-025-06495-7

Keywords: Pediatric anesthesia, HR020602, propofol, safety, efficacy, general anesthesia, multicenter study.

MicroRNAs, often referred to as miRNAs, are small non-coding RNA molecules that play crucial roles in regulating gene expression. The specific function of MiR-483-5p has garnered attention for its potential influence on various biological processes, particularly during and after surgical procedures. The unique metabolic and physiological profiles of children necessitate specialized research; therefore, identifying reliable biomarkers that could predict adverse events in pediatric patients under general anesthesia is a significant leap forward.

The study by Zhao and colleagues meticulously delves into the implications of MiR-483-5p on respiratory events, notably concerning hypoxemia and bronchospasm, which present considerable risks during procedures involving general anesthesia. As healthcare professionals continue to strive for improved safety measures in pediatric surgery, the need for preoperative assessments informed by robust biomarkers becomes increasingly apparent. Such advancements could lead to tailored anesthetic plans, thus minimizing the potential for respiratory complications.

It is essential to recognize the critical context surrounding the research findings. Perioperative respiratory adverse events are not only distressing for the healthcare team but, more crucially, they pose grave risks to patient safety and recovery outcomes. The discovery of MiR-483-5p as a reliable biomarker is thus a significant contribution, as it may allow clinicians to identify at-risk patients more accurately, improving preoperative screening processes.

Through rigorous analytical methods, the research highlights how elevated levels of MiR-483-5p correlate with increased incidents of respiratory complications during surgeries. This correlation emphasizes the need for integrating such miRNA evaluations into routine assessments. Implementing these biomarkers could pave the way toward proactive interventions, tailoring anesthesia approaches to individual patient profiles for enhanced safety and efficacy.

Moreover, the implications of MiR-483-5p extend beyond mere identification of at-risk patients. Understanding the mechanisms by which MiR-483-5p influences respiratory function could offer insights into designing targeted therapies that mitigate the risk of adverse events. Such therapeutic strategies could potentially utilize pharmacological modulation of this microRNA to improve respiratory stability among pediatric patients during anesthesia.

The findings presented by Zhao et al. contribute to a growing body of literature that seeks to bridge the gap between molecular biology and clinical practice in anesthesiology. As the medical community grapples with the diverse challenges of pediatric anesthesia, leveraging biomarkers like MiR-483-5p could greatly enhance patient management, ensuring that interventions are not only reactive but also proactive.

It is imperative for anesthesiologists, pediatric surgeons, and critical care specialists to remain abreast of developments in biomarker research. As further studies validate MiR-483-5p’s utility, this could lead to broader adoption in clinical protocols, marking a pivotal step toward safer surgical experiences for children. The integration of molecular diagnostics into the anesthetic workflow embodies the future of personalized medicine, focusing on patient-specific risks rather than adopting a one-size-fits-all approach.

This innovation also augments efforts towards standardizing safety protocols that guide preoperative planning. The ability to stratify patients based on biomarker expression aligns with contemporary practices that prioritize enhanced recovery and minimize postoperative complications. Future studies will be crucial in corroborating these preliminary findings, establishing MiR-483-5p as a standard component of pre-anesthetic evaluation metrics.

Therein lies the transformative potential of this research. As healthcare systems worldwide grapple with increasing surgical volume and complexity, identifying reliable metrics that streamline patient evaluation becomes indispensable. The collaboration between molecular biologists and clinical practitioners marks a progressive trend that could redefine how health systems manage surgical care, particularly in vulnerable populations such as pediatric patients.

In conclusion, the exploration of MiR-483-5p as a biomarker for perioperative respiratory adverse events in children presents a renaissance in the multifaceted field of pediatric anesthesia. While challenges remain, the prospects outlined in the study furnish hope for a future where surgical interventions are safer, more effective, and meticulously tailored to each patient’s needs. This research not only heralds a new epoch of understanding in anesthesiology but also reinforces the pressing need for an innovation-driven approach to the challenges posed by pediatric surgical care.

Ultimately, continuing investigations into MiR-483-5p could prove to be a game-changer, fostering a new paradigm in how clinicians anticipate and manage potential complications in pediatric anesthesia. This ongoing pursuit of knowledge highlights the critical interconnection between basic science and clinical application, urging an era of health care defined by precision, safety, and patient empowerment.

As the scientific community eagerly awaits further developments in this domain, the need for multidisciplinary collaboration has never been more pronounced. By bridging the gap between laboratory discoveries and clinical implementation, we can cultivate an environment where treatment protocols are not only informed by empirical evidence but also guided by innovations emerging from the forefront of research.

The future of pediatric anesthesia may very well hinge on advancements like those exemplified by MiR-483-5p, illuminating a path toward enhanced safety, better outcomes, and a deeper understanding of the complexities inherent in surgical care for children.

Subject of Research: MiR-483-5p as a biomarker in pediatric anesthesia.

Article Title: MiR-483-5p has the potential to serve as a biomarker in perioperative respiratory adverse events in children under general anesthesia.

Article References:

Zhao, X., Yan, R., Liu, J. et al. MiR-483-5p has the potential to serve as a biomarker in perioperative respiratory adverse events in children under general anesthesia.
BMC Pediatr (2026). https://doi.org/10.1186/s12887-025-06483-x

Image Credits: AI Generated

DOI:

Keywords: MiR-483-5p, biomarker, pediatric anesthesia, respiratory adverse events, microRNA, perioperative care.

Emergence delirium is characterized by a state of acute confusion, agitation, and inconsolable crying during the immediate recovery phase from anesthesia. While it has been observed anecdotally for decades, the intricate mechanisms and predictive factors associated with ED in infants and toddlers have remained elusive. This new study spearheaded by Zhao, Hashimoto, Ding, and colleagues represents the first large-scale systematic evaluation focused exclusively on pediatric patients under sevoflurane anesthesia, aiming to disentangle the multifactorial risks and to correlate ED with subsequent negative postoperative behavioral changes (NPOBC).

The investigation enrolled a sizeable cohort of infant-toddler patients scheduled for fundus examinations under sevoflurane sedation. Researchers meticulously assessed behavioral patterns emerging from induction through recovery, employing validated scales designed to quantify delirium severity and postoperative behavioral disruptions. This robust methodology allowed for unprecedented granularity in tracking the temporal evolution of neurobehavioral responses post-anesthesia, laying bare the often subtle, yet clinically significant, nuances of emergence delirium.

Sevoflurane’s pharmacokinetics, with its low blood-gas partition coefficient, ensures rapid induction and recovery, a trait beneficial in outpatient pediatric procedures. However, the same properties may underpin a sudden neurophysiological shift during emergence, potentially triggering neuroexcitatory pathways implicated in delirium. The study posits that this abrupt cerebral transition can overwhelm immature neural circuits in infants and toddlers, rendering them vulnerable to ED. This novel pathophysiological insight contributes to a growing dialogue on neurodevelopmental susceptibility during anesthesia in early childhood.

Coupled with pharmacodynamics, patient-specific characteristics emerged as vital determinants of ED risk. Age was inversely correlated with incidence; the younger the patient, particularly those under two years, the higher the propensity for emergence delirium. This observation aligns with the understanding that neurodevelopmental immaturity exacerbates vulnerability to anesthetic-induced perturbations in consciousness. Moreover, preoperative anxiety syndromes and innate temperament traits were implicated as contributory, underscoring the psychosocial dimensions that interplay with biological susceptibilities.

A particularly influential finding was the association between the duration of sevoflurane exposure and the intensity of ED symptoms. Prolonged anesthetic administration correlated with more severe and protracted delirium episodes, suggesting dose-dependent neurotoxic effects or an augmented destabilization of neural homeostasis. This dose-response relationship heightens the urgency for optimizing anesthetic protocols, especially in elective pediatric procedures, to minimize exposure duration without compromising procedural efficacy.

Crucially, the study elucidated a compelling link between the occurrence of emergence delirium and subsequent negative postoperative behavioral changes. Infants and toddlers exhibiting ED were significantly more likely to demonstrate adverse behaviors post-discharge, including heightened nocturnal anxiety, feeding difficulties, and separation anxiety. These downstream behavioral perturbations persisted over weeks, indicating that ED may serve as a harbinger of longer-lasting neuropsychiatric vulnerabilities warranting early intervention and parental guidance.

Underlying the association between emergence delirium and long-term behavioral effects are complex neurochemical cascades involving neurotransmitter dysregulation and inflammatory responses triggered by anesthetic exposure. The authors hypothesize that early disruption of synaptic maturation and heightened neuroinflammation may precipitate these negative behavioral sequelae. As such, the study pioneers a holistic understanding shifting the focus beyond immediate anesthesia recovery to encompass broader neurodevelopmental trajectories impacted by anesthetic insults.

The implications of these findings reverberate through clinical practice, compelling pediatric anesthesiologists to reevaluate preoperative assessment and anesthetic management strategies. Incorporating predictive risk factor screening for emergence delirium might facilitate personalized anesthetic plans, including anxiolytic premedication or alternative sedation schemes. Moreover, heightened postoperative monitoring and supportive behavioral interventions become imperative to mitigate the enduring impact of NPOBC, aiming to preserve the neuropsychological well-being of pediatric patients.

From a research perspective, the study opens avenues for exploring potential neuroprotective agents capable of modulating the neuroinflammatory pathways implicated in emergence delirium. Investigations into non-pharmacologic interventions such as parental presence during induction or sensory modulation techniques might also attenuate the distress associated with awakening from anesthesia. The interplay between genetic predispositions, environmental stressors, and anesthetic pharmacology poised to be fertile ground for future inquiry.

The work by Zhao and colleagues represents a critical advance in pediatric anesthesiology, shining a light on a previously underrecognized neurobehavioral complication. It underscores the necessity for multidisciplinary collaboration among anesthesiologists, neurologists, psychologists, and pediatricians to devise comprehensive care models that prioritize both the immediate and long-term neurodevelopmental health of young patients undergoing anesthesia.

In bridging intensive clinical observations with molecular hypotheses, the study epitomizes translational medicine, demonstrating how bedside findings can catalyze bench research and vice versa. Its emphasis on a vulnerable pediatric subset propels advocacy for stringent anesthetic safety protocols, tailored to preserve neurocognitive integrity during a pivotal developmental window. As pediatric sedation techniques evolve, this research will remain a cornerstone reference guiding evidence-based improvements.

The study’s methodological rigor, including its prospective design, sizable sample, and validated outcome measures, lends robust credibility to its conclusions. Notwithstanding, the authors acknowledge limitations including the single-center setting and the focus on a specific procedural context, which may affect generalizability. Multicenter studies with heterogeneous populations will be essential to validate and expand upon these findings, ensuring broad applicability across pediatric anesthetic practice.

Importantly, the relationship delineated between sevoflurane anesthesia, emergence delirium, and negative postoperative behavioral changes calls for proactive parental education. Enhancing caregiver awareness about possible postoperative behavioral manifestations could promote early recognition and timely medical consultation, ultimately improving patient outcomes. Parental engagement emerges as a therapeutic adjunct complementing medical strategies.

In sum, this pioneering study offers a comprehensive panorama of emergence delirium in infants and toddlers subjected to sevoflurane anesthesia, charting critical risk factors and unveiling the consequential link to persistent behavioral disorders. Its insights offer a clarion call for clinicians and researchers alike to refine anesthetic protocols, augment perioperative care, and deepen our understanding of pediatric neurobehavioral health post-anesthesia. The ramifications extend beyond pediatrics, informing broader neurodevelopmental research and patient safety paradigms.

As the field advances, this work exemplifies the potential of focused pediatric anesthesia research to uncover intricacies of brain-behavior interplay, driving future innovations that safeguard the most vulnerable patients. The heightened awareness and evidence-based strategies emanating from this study herald a new era where anesthesia not only ensures procedural success but also champions lifelong neurological well-being.

Subject of Research: Risk factors for emergence delirium in infant-toddlers undergoing sevoflurane anesthesia and its impact on negative postoperative behavioral changes

Article Title: Risk factors for emergence delirium in infant-toddlers undergoing sevoflurane anesthesia and its impact on negative postoperative behavioral changes

Article References:
Zhao, W., Hashimoto, K., Ding, W. et al. Risk factors for emergence delirium in infant-toddlers undergoing sevoflurane anesthesia and its impact on negative postoperative behavioral changes. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04608-7

Image Credits: AI Generated

DOI: 10.1038/s41390-025-04608-7

Sedation in pediatric patients, particularly neonates and infants, demands an intricate balance. These patients present unique anatomical and physiological characteristics distinct from older children and adults, such as immature respiratory control, variable airway anatomy, and increased susceptibility to airway obstruction. The decision to position these vulnerable patients laterally, as opposed to the more traditional supine position, is not merely a matter of convenience but involves careful evaluation of airway patency and risk mitigation.

One of the primary arguments supporting lateral positioning during sedation centers on the maintenance of airway patency. The lateral position can facilitate spontaneous drainage of secretions and reduce the incidence of airway obstruction, a known complication in sedated infants. Unlike older children, the very young possess a relatively large tongue in proportion to the oral cavity, prone to cause airway collapse when muscle tone decreases under sedation. Placing the patient laterally may counterbalance this anatomical predisposition by allowing gravity to assist in keeping the airway open.

Moreover, the lateral position has been historically applied in cases of airway surgery or procedures necessitating scrutiny of upper respiratory pathways. Extending this practice to routine sedation scenarios demands rigorous assessment of its benefits against potential downsides. Pac-Soo and Ma’s correspondence underscores the paucity of high-quality randomized controlled trials that definitively declare one position superior in terms of safety and efficacy for sedated infants.

Respiratory mechanics in the lateral versus supine position diverge significantly in newborns and infants. In the supine position, the weight of the abdominal contents can impede diaphragmatic excursion, potentially reducing functional residual capacity and predisposing to atelectasis. Lateral positioning may alleviate this mechanical restriction, promoting better ventilation-perfusion matching. However, the lateral position can introduce variability in hemodynamics and complicate the monitoring of certain vital signs, such as pulse oximetry, which are critical during sedation.

Pac-Soo and Ma highlight the need to weigh these physiological nuances against the context of the procedural requirements and the expertise of the clinical team. In facilities with comprehensive monitoring and skilled anesthesia providers, lateral sedation might offer advantages that enhance patient safety. Conversely, scenarios that lack such robust support systems may favor the familiarity and logistical simplicity of the supine position.

Another compelling aspect of this debate is the potential psychological impact on caregivers and families observing sedation approaches. The lateral position, which may appear unconventional, could provoke concerns, underscoring the importance of incorporating clear communication and education into sedation protocols. Transparency about the rationale for positioning and associated risks is essential to maintaining trust and ensuring informed consent.

Pharmacological considerations also intertwine with positional choices. Sedative agents such as dexmedetomidine and midazolam affect central nervous system activity differently, influencing muscle tone, respiratory drive, and airway reflexes. The lateral position may either mitigate or exacerbate sedative-related airway compromise depending on these drug effects, an interaction that demands further empirical elucidation.

The intricate balance of oxygenation and ventilation during pediatric sedation further complicates this clinical equation. Pulse oximetry and capnography are vital in continuous assessment; however, the lateral position can affect the accuracy and interpretation of these monitoring modalities, hence clinical teams must maintain heightened vigilance. Adjustments in sensor placement and monitoring techniques may be required to adapt optimally to lateral positioning.

Pac-Soo and Ma also draw attention to rare but serious complications, such as aspiration, which sedation protocols aim to prevent. The lateral position theoretically reduces the risk by facilitating drainage of gastric contents and secretions away from the airway. Nevertheless, this benefit is contingent upon precise execution of sedation and positioning protocols to avoid inadvertent head rotation or neck flexion that could negate airway protection.

Incorporating the lateral position into standard sedation practices may also necessitate revisions in anesthesia training curricula. Practitioners must become adept at patient handling, airway maneuvers, and emergency interventions tailored to lateral sedation scenarios. Simulation-based training could play a pivotal role in preparing anesthesiologists and nursing staff to respond promptly to position-specific challenges.

From a research standpoint, the letter by Pac-Soo and Ma serves as a catalyst for in-depth investigations. Prospective studies comparing lateral versus supine sedation with comprehensive endpoints—including oxygen saturation, airway events, hemodynamic stability, and procedural success—are imperative. Additionally, subgroup analyses according to age, comorbidities, and sedative regimens could refine guidelines for personalized sedation practices.

Technological advancements hold promise in enhancing safety in lateral sedation. Innovations such as automated patient positioning systems, integrated multi-parameter monitoring platforms, and artificial intelligence-driven prediction models could facilitate real-time adjustments and early detection of complications unique to lateral sedation.

Ethical considerations must not be overlooked. The adoption of lateral sedation protocols should be grounded in robust evidence to ensure patient welfare and uphold medical standards. As with any clinical innovation, transparency in reporting adverse events and outcomes is critical to iteratively refine practices and inform consensus guidelines.

The dialogue ignited by Pac-Soo and Ma’s inquiry epitomizes the dynamic nature of pediatric anesthesia, where evolving evidence continuously informs best practices. Sedating very young patients laterally may represent a shift toward personalized, physiology-informed sedation strategies, but it also challenges established conventions and demands a multi-dimensional appraisal.

In conclusion, whether the lateral position should become routine during sedation for very young patients hinges upon a confluence of factors—anatomical, physiological, pharmacological, technical, and ethical. Pac-Soo and Ma’s reflection invites the pediatric anesthesia community to critically evaluate existing protocols and embrace a research agenda poised to optimize sedative care tailored for the youngest and most vulnerable patients.

Subject of Research: The exploration of optimal patient positioning (lateral vs. supine) during sedation of very young pediatric patients, focusing on airway safety, physiological implications, and procedural outcomes.

Article Title: Should we sedate very young patients in the lateral position?

Article References:
Pac-Soo, C.K., Ma, D. Should we sedate very young patients in the lateral position?. World J Pediatr 21, 550–551 (2025). https://doi.org/10.1007/s12519-025-00930-6

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12519-025-00930-6